Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
CA 2768682 C · Owner: Endorecherche, Inc. · Inventors: Labrie, Fernand
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel methods for the medical treatment and/or inhibition of the development of osteoporosis breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warm-blooded animals including humans involving administration of selective estrogen receptor modulator particularly compounds having general structure (I) and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone dehydroepiandrosterone sulfate, androst-5-ene- 3.beta.17.beta.-diol and compounds converted in vivo to one of the foregoing precursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 10, 1999 and granted March 18, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 10, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 10, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.